Dr. Rohan Garje, MD

Dr. Garje practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Garje's NPI, 1184902884, was assigned on July 28, 2011. Dr. Garje graduated from Osmania Medical College NTR UHS in 2009. Dr. Garje holds Florida license ME157365.

Dr. Garje's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Garje's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. Dr. Garje is also affiliated with South Miami Hospital. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Garje to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Garje practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Garje's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Garje is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Garje's licenses on file in 3 states: Florida, Iowa and Ohio.

Dmand AI lists chronic leukemia, lung cancer, multiple myeloma and prostate cancer among the conditions Dr. Garje treats.

CMS data shows 1,545 Medicare services from Dr. Garje across 5 procedure codes in 2024, for 194 Medicare patients. Medicare paid $94,491 for them.

CMS counts 194 Medicare patients who saw Dr. Garje in 2024. The largest group is 75 to 84, with 88 patients. 75% of them have cancer, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Garje's median patient age at 71, with 11% women.

In 2024, Dr. Garje wrote 517 Medicare Part D claims for 151 patients. 60% of them were for generic drugs. CMS names the drug for 359 of them, across 12 drugs with 11 or more claims each, at $2,287,633 in total drug cost. In 2023, CMS named 83 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Garje for performance year 2024, reported as part of a group. Dr. Garje accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Garje as offering telehealth.

Dmand AI links 56 papers to Dr. Garje, published from 2017 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Urinary Bladder Neoplasms. Dr. Garje has published most often in J Clin Oncol. Dr. Garje's most frequent co-authors are Andrew John Armstrong, MD, Mehmet Asim Bilen, MD and Rana Ramzi McKay, MD.

Dmand AI links Dr. Garje to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Transitional Cell and Carcinoma.

CMS Open Payments shows 35 general payments to Dr. Garje from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Novartis Pharmaceuticals Corporation paid the most, $9,958.

Dmand AI lists 2 awards for Dr. Garje, most recently Doctor’s Dilemma Jeopardy competition in 2013. Dr. Garje serves on ASCO Methodology Committee, ASCO Early Career and Trainee committee and ASCO Evidence Based Medicine Committee.

Dr. Garje graduated from Osmania Medical College NTR UHS in 2009. Dr. Garje is a member of ACP and ASCO.

Dr. Garje is in network with 12 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.